Clinical Trial Update: Sublingual Misoprostol to Reduce Blood Loss During Elective Cesarean Delivery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sublingual misoprostol to reduce blood loss during elective cesarean delivery for postpartum hemorrhage; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postpartum Hemorrhage

Drugs mentioned

• MISOPROSTOL (Misoprostol)

Snippet

Sponsor: Ain Shams Maternity Hospital | Conditions: Hemorrhage Postpartum | Phase 2 | Status: UNKNOWN